Abstract
The records of 194 patients with thyroid carcinoma treated with 131I, representing all cases thus treated in Denmark from 1948 to 1972, were reviewed. Two cases of myeloid leukaemia were found compared with 0·097 expected cases of non-lymphocytic leukaemia (0·05 > P > 0·01). In 5 series of 131I treated thyroid carcinomata, 10 cases of myeloid leukaemia occurred in a total of 487 patients, corresponding to a frequency of leukaemia of about 2%. These findings appear to show that 131I treatment of thyroid carcinoma is associated with a certain risk of development of leukaemia. This risk must be considered when treatment of localized thyroid carcinoma is planned.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Brincker, H., Hansen, H. & Andersen, A. Induction of Leukaemia by 131I Treatment of Thyroid Carcinoma. Br J Cancer 28, 232–237 (1973). https://doi.org/10.1038/bjc.1973.142
Issue Date:
DOI: https://doi.org/10.1038/bjc.1973.142
This article is cited by
-
Therapy-related acute myeloid leukemia following radioactive iodine treatment for thyroid cancer
Cancer Causes & Control (2016)
-
Chronic lymphocytic leukemia radiogenicity: a systematic review
Cancer Causes & Control (2007)
-
Cancer in iodine-131 exposed patients
Journal of Endocrinological Investigation (1995)
-
The clinician and the thyroid
European Journal of Nuclear Medicine (1991)